C4 Therapeutics Stock Performance
| CCCC Stock | USD 2.47 0.07 2.76% |
The firm owns a Beta (Systematic Risk) of 2.19, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, C4 Therapeutics will likely underperform. At this point, C4 Therapeutics has a negative expected return of -0.43%. Please make sure to confirm C4 Therapeutics' total risk alpha, potential upside, and the relationship between the standard deviation and maximum drawdown , to decide if C4 Therapeutics performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days C4 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in January 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 130 M | |
| Total Cashflows From Investing Activities | -51.3 M |
C4 Therapeutics Relative Risk vs. Return Landscape
If you would invest 357.00 in C4 Therapeutics on September 14, 2025 and sell it today you would lose (110.00) from holding C4 Therapeutics or give up 30.81% of portfolio value over 90 days. C4 Therapeutics is currently does not generate positive expected returns and assumes 5.4466% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than CCCC, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
C4 Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for C4 Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as C4 Therapeutics, and traders can use it to determine the average amount a C4 Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0785
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CCCC |
Based on monthly moving average C4 Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of C4 Therapeutics by adding C4 Therapeutics to a well-diversified portfolio.
C4 Therapeutics Fundamentals Growth
CCCC Stock prices reflect investors' perceptions of the future prospects and financial health of C4 Therapeutics, and C4 Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CCCC Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (2.11) % | ||||
| Current Valuation | 119.62 M | ||||
| Shares Outstanding | 96.91 M | ||||
| Price To Book | 1.62 X | ||||
| Price To Sales | 8.18 X | ||||
| Revenue | 35.58 M | ||||
| EBITDA | (103.37 M) | ||||
| Cash And Equivalents | 307.78 M | ||||
| Cash Per Share | 6.29 X | ||||
| Total Debt | 65.76 M | ||||
| Debt To Equity | 0.25 % | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (65.16 M) | ||||
| Earnings Per Share | (1.67) X | ||||
| Total Asset | 349.6 M | ||||
| Retained Earnings | (633.7 M) | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 49 K | ||||
About C4 Therapeutics Performance
By analyzing C4 Therapeutics' fundamental ratios, stakeholders can gain valuable insights into C4 Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if C4 Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if C4 Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. C4 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 121 people.Things to note about C4 Therapeutics performance evaluation
Checking the ongoing alerts about C4 Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for C4 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| C4 Therapeutics generated a negative expected return over the last 90 days | |
| C4 Therapeutics has high historical volatility and very poor performance | |
| C4 Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 35.58 M. Net Loss for the year was (105.32 M) with loss before overhead, payroll, taxes, and interest of (81.66 M). | |
| C4 Therapeutics currently holds about 307.78 M in cash with (65.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 73.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Cassava Pops After CEO Buys 150K Shares |
- Analyzing C4 Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether C4 Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining C4 Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating C4 Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of C4 Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of C4 Therapeutics' stock. These opinions can provide insight into C4 Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |